Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

about

Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.Next generation of immune checkpoint therapy in cancer: new developments and challenges.Breast Cancer Immunotherapy: An Update.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

P2860

Q52603627-4068743C-4345-44FB-AEC0-566022F43FEE Q52653710-7528998A-EF32-4821-9EE8-F62CBFDC1D4B Q55360303-925BC69E-E57E-419A-9CA5-28F4FE99E2A9 Q56892924-55F5ADD2-C21A-4C04-9295-B7ADE85ABD8A

P2860

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Item

http://www.wikidata.org/entity/Q47325431

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

@en

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

@nl

type

Item

label

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

@en

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

@nl

prefLabel

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

@en

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

@nl

P1476

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

@en

P2093

Aura Muntasell

http://www.w3.org/2001/XMLSchema#string

Rienk Offringa

http://www.w3.org/2001/XMLSchema#string

P2860

T cell receptor signalling in the control of regulatory T cell differentiation and function

Immunotherapy for cancer in the central nervous system: Current and future directions

Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors

Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer

Molecular and cellular insights into T cell exhaustion

Integrating canonical and metabolic signalling programmes in the regulation of T cell responses

Molecular mechanisms of T cell co-stimulation and co-inhibition

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

Nivolumab plus ipilimumab in advanced melanoma.

P304

e1371896

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/2162402X.2017.1371896

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29209572

http://www.w3.org/2001/XMLSchema#string

P932

5706611

http://www.w3.org/2001/XMLSchema#string

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

about

P2860

P2860

Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932